Table 2.
Comparison of Risk Assessment Models
| Item | Khorana Score∗ | Vienna CATS Score | PROTECHT Score | CONKO Score |
|---|---|---|---|---|
| Pancreatic or gastric cancer (very-high-risk tumors) | +2 | +2 | +2 | +2 |
| Lung, gynecologic, lymphoma, bladder, or testicular (high-risk tumors) | +1 | +1 | +1 | +1 |
| Pre-chemotherapy Hb of <10 g/dl or erythropoietin-stimulating agents | +1 | +1 | +1 | +1 |
| Pre-chemotherapy white blood cell count of >1 × 109/l | +1 | +1 | +1 | +1 |
| Pre-chemotherapy platelet count of ≥350 × 109/l | +1 | +1 | +1 | +1 |
| Body mass index of >35 kg/m2 | +1 | +1 | +1 | — |
| D-dimer of >1.44 mg/l | — | +1 | — | — |
| Soluble P-selectin of >53.1 ng/l | — | +1 | — | — |
| Platinum-based or gemcitabine chemotherapy | — | — | +1 | — |
| WHO performance status ≥2 | — | — | — | +1 |
CATS = cancer-associated thrombosis score; CONKO = Charité Onkologie; Hb = hemoglobin; PROTECHT = Prophylaxis Thromboembolic Events Chemotherapy; WHO = World Health Organization.
∗
Total score: 0 = low risk; 1 to 2 = intermediate risk; ≥3 = high risk. See https://www.mdcalc.com/khorana-risk-score-venous-thromboembolism-cancer-patients.